ROCO
4911
Market cap86mUSD
Nov 12, Last price
48.75TWD
Name
G&E Herbal Biotechnology Co Ltd
Chart & Performance
P/E
26.59
P/S
10.90
EPS
1.83
Div Yield, %
1.24%
Shrs. gr., 5y
—
Rev. gr., 5y
-20.15%
Revenues
249m
+37.25%
Net income
102m
+40.97%
CFO
135m
+18.68%
Dividend
Aug 20, 20240.6049 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
G&E Herbal Biotechnology Co., Ltd., a biopharmaceutical company, focuses on the development and commercialization of novel botanical extraction technology and products. It offers botanical anti-aging cosmetic products, such as facial foam cleanser and cleansing essence, botanical extract toner, lightening lotion, essential oil, and moisturizing serum and cream; SR-100 botanical essence and bromelain illuminating cleansing mousse; and hepato protective agent capsules. The company also provides botanical healthcare products comprising ArthrEnergy, Jujubes Polysaccharide, Diabecut, HepatoClean, Astragali Radix, Goji, Prosta, and SR-100 capsules; and adult products. In addition, it is developing Solarise injection for the treatment of gynecologic, head, and neck cancer; Apocin capsule to treat non-small cell lung cancer; and SR-T100 Gel for the treatment of common and genital warts. Further, the company manufactures technology development for various dietary supplements, as well as provides technical advisory services to other biotechnology organizations. G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||